NeuroSense is advancing PrimeC, a dual-mechanism oral therapy targeting neuroinflammation and oxidative stress in ALS, into Phase 3 trials after Phase 2b data demonstrated slowed disease progression and survival benefit. The compound addresses multiple pathological drivers simultaneously rather than targeting single endpoints, representing a shift in how neurodegenerative disease progression is being conceptualized and treated.
Key Points
- PrimeC combines ciprofloxacin and celecoxib to address neuroinflammation, oxidative stress, and iron
- Phase 2b PARADIGM trial showed slowed progression with biomarker activity and meaningful survival ex
- Phase 3 PARAGON trial enrolling 300 participants; FDA cleared for accelerated approval pathway
Longevity Analysis
ALS represents a disease of compounding system failure where inflammation, metabolic dysfunction, and neural degeneration create a self-perpetuating cascade. Most treatments target a single point in this cascade and fail. PrimeC's multi-target approach—addressing oxidative burden, dysregulated iron handling, and inflammatory signaling simultaneously—aligns with how resistant neurodegenerative diseases actually progress. The Phase 2b survival signal is significant because it suggests that intervening at multiple nodes of pathology can alter the fundamental trajectory, not merely slow it marginally. This matters for longevity because ALS patients who achieve meaningful disease stabilization gain years of preserved cognition and function—a direct measure of compressed morbidity. The biomarker activity (microRNAs) also strengthens the biological plausibility that the mechanism proposed is actually engaged.
Original published by Longevity.Technology.